Healthcare / BiotechnologyNasdaqGS
$4.34
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-65.0M · quality 67.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$855M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-43.7%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
-1.3%
FCF CAGR
—
FCF margin
-281.5%
FCF / Net income
1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $14.1M · net income $-33.5M · FCF $-39.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $14.1M | $14.1M | $6.2M | $18.1M | $39.0M | $11.0M | $6.9M | $6.0M | $5.9M | $10.7M | $1.5M | $23.3M | $15.0M | $15.5M | $14.1M | $16.8M |
| Net Income | $-33.5M | $-33.5M | $-69.9M | $-72.8M | $-69.5M | $-76.2M | $-63.7M | $-153.7M | $-57.1M | $-84.4M | $-384.2M | $-62.7M | $-38.8M | $-14.1M | $29.6M | $-10.1M |
| EPS | -0.17 | -0.17 | -0.38 | -0.44 | -0.46 | -0.83 | -1.00 | — | -1.21 | -1.56 | -7.24 | -1.38 | -1.80 | -0.92 | 2.07 | -0.89 |
| Operating Margin | -271.0% | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | -2394.0% | -1510.2% | -1036.7% | -32973.8% | -446.5% | -223.6% | -78.6% | -91.8% | -63.6% |
| Net Margin | -237.9% | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | -2557.4% | -959.8% | -788.9% | -25765.5% | -269.5% | -259.7% | -90.9% | 209.9% | -60.0% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $-39.6M | $-39.6M | $-65.0M | $-86.9M | $-35.9M | $-68.3M | $-51.7M | $-71.6M | $-69.0M | $-55.9M | $-61.9M | $-58.7M | $-13.5M | $-7.5M | $32.9M | $-7.9M |
| Returns | ||||||||||||||||
| ROE | -43.7% | -43.7% | -71.8% | -68.7% | -50.8% | -45.0% | -62.5% | -211.3% | -28.5% | -46.3% | -189.2% | -11.5% | -44.1% | -23.8% | 72.4% | -192.9% |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 128.2% | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | 15.0% | 1.1% | -44.4% | 617.6% | -93.6% | 55.7% | -3.3% | 9.6% | -16.1% | — |
| EPS Growth | 55.3% | 55.3% | 13.6% | 4.3% | 44.6% | 17.0% | — | — | 22.4% | 78.5% | -424.6% | 23.3% | -95.7% | -144.4% | 332.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.